Digital data has expanded beyond imagination, and can create some serious issues for privacy and human rights, especially when it comes to the sensitive health data now being used in the battle against Covid-19. Our new series, SI Opener, analyzes the problems faced trying to trade off privacy with tracking technology.SI Opener 28 May 2020
The Covid-19 crisis has brought unprecedented volatility to markets and is set to usher in a global recession. We would like to help you navigate the turbulence through our series of insights, outlooks, webinars and portfolio manager's updates.
While Covid-19 continues to affect markets, we will publish frequent updates on all our key strategies, offering insight and expectations from our portfolio managers.
The information contained in the website is solely intended for professional investors. Some funds shown on this website fall outside the scope of the Dutch Act on the Financial Supervision (Wet op het financieel toezicht) and therefore do not (need to) have a license from the Authority for the Financial Markets (AFM).
The funds shown on this website may not be available in your country. Please select your country website (top right corner) to view the products that are available in your country.
Neither information nor any opinion expressed on the website constitutes a solicitation, an offer or a recommendation to buy, sell or dispose of any investment, to engage in any other transaction or to provide any investment advice or service. An investment in a Robeco product should only be made after reading the related legal documents such as management regulations, prospectuses, annual and semi-annual reports, which can be all be obtained free of charge at this website and at the Robeco offices in each country where Robeco has a presence.